For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

JEVTANA is a NCCN designated Category 1 Second-line Therapy1,2

A Novel Taxane With a Unique Chemical Structure2

The Novel Structure of JEVTANA Demonstrates Its Pharmacodynamic Properties at the Cellular Level2

In vitro, JEVTANA is a substrate of P-gp (P-glycoprotein), but with a low affinity. JEVTANA is not a substrate of:

  • Efflux pumps MRP1 (multidrug-resistance protein 1), MRP2 (multidrug-resistance protein 2), BCRP (breast cancer resistance protein).
  • SLC transporters OCT1 (organic cation transporter), OATP1B1 or OATP1B3 (organic anion transporting polypeptides).



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave

You are leaving to view another Sanofi Genzyme Corporation website.